147 related articles for article (PubMed ID: 37059268)
1. Androgen Receptor Transcriptionally Inhibits Programmed Death Ligand-1 Expression and Influences Immune Escape in Bladder Cancer.
Sun A; Luo Y; Xiao W; Zhu Z; Yan H; Miao C; Zhang W; Bai P; Liu C; Yang D; Shao Z; Song J; Wu Z; Chen B; Xing J; Wang T
Lab Invest; 2023 Jul; 103(7):100148. PubMed ID: 37059268
[TBL] [Abstract][Full Text] [Related]
2. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M
Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177
[TBL] [Abstract][Full Text] [Related]
3. Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.
Liu Q; You B; Meng J; Huang CP; Dong G; Wang R; Chou F; Gao S; Chang C; Yeh S; Xu W
Cancer Gene Ther; 2022 Dec; 29(12):1988-2000. PubMed ID: 35915245
[TBL] [Abstract][Full Text] [Related]
4. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
5. Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
7. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.
Toren P; Brisson H; Simonyan D; Hovington H; Lacombe L; Bergeron A; Fradet Y
World J Urol; 2021 May; 39(5):1549-1558. PubMed ID: 32676741
[TBL] [Abstract][Full Text] [Related]
10. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
11. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
12. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
13. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
Lv J; Wu Q; Li K; Bai K; Yu H; Zhuang J; Sun H; Yang H; Yang X; Lu Q
Int J Biol Sci; 2023; 19(12):3744-3761. PubMed ID: 37564199
[No Abstract] [Full Text] [Related]
14. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals.
Ou Z; Wang Y; Liu L; Li L; Yeh S; Qi L; Chang C
Oncotarget; 2015 Sep; 6(28):26065-78. PubMed ID: 26305549
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
16. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation.
Hsieh TF; Chen CC; Ma WL; Chuang WM; Hung XF; Tsai YR; Lin MH; Zhang Q; Zhang C; Chang C; Shyr CR
Oncol Rep; 2013 Dec; 30(6):2917-22. PubMed ID: 24126741
[TBL] [Abstract][Full Text] [Related]
18. Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
Wu Y; Xu Y; He S; Li Y; Feng N; Fan J; Gong Y; Li X; Zhou L
Heliyon; 2023 Mar; 9(3):e13707. PubMed ID: 36873531
[TBL] [Abstract][Full Text] [Related]
19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma -
Madureira AC
Front Immunol; 2022; 13():955000. PubMed ID: 36148227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
